Preclinical News and Research

RSS

Pieris, Zydus Cadila partner to develop and commercialize Anticalin-based protein therapeutics

Zydus Cadila, an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products, and Pieris AG, a next generation therapeutic protein R&D company, have entered into an alliance for development and commercialization of multiple novel Anticalin-based protein therapeutics, both companies announced today.

16 Oct 2013

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Crown Bioscience, Inc., a leading global drug discovery and development service company, today announces that it has entered into a collaboration with Xstrahl Ltd, a leading designer and manufacturer of X-Ray solutions for radiation biology research.

From Xstrahl 15 Oct 2013

Tepnel Pharma Services uses Hologic’s Invader Plus technology to offer genotyping, CNV service

Tepnel Pharma Services, a division of Hologic, Inc., is now using Hologic’s proprietary Invader and Invader Plus technology as part of its Molecular Genetic Services offering, enabling it to offer customers a more cost effective and high throughput genotyping and copy number variation service.

From Hologic, Inc. 15 Oct 2013

New optical imaging technique can accurately differentiate breast cancer subtypes

An optical imaging technique that measures metabolic activity in cancer cells can accurately differentiate breast cancer subtypes, and it can detect responses to treatment as early as two days after therapy administration, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.

15 Oct 2013

Novartis Inks Agreement For Immunogen's "TAP" ADC Technology

...

11 Oct 2013

Yale Launches Collaboration With ARO, CRO Partners

...

11 Oct 2013

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

...

10 Oct 2013

Constellation Pharmaceuticals awarded grant to facilitate study of epigenetic control of inflammation

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company in the field of epigenetics, today announced that it has been awarded a research grant in collaboration with the University of Pittsburgh School of Medicine from the Cystic Fibrosis Foundation to explore the potential use of BET bromodomain inhibitors for the control of inflammation in cystic fibrosis.

10 Oct 2013

Allegro receives FDA IND approval to initiate Phase II clinical studies of ALG-1001 in AMD, VMT patients

Allegro Ophthalmics, LLC, a company dedicated to establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of vascular eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to begin two Phase II clinical studies of ALG-1001.

10 Oct 2013

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis.

10 Oct 2013

Catalyst, Isu Abxis To Develop Hemophilia B Candidate

...

9 Oct 2013

Compugen drug candidate prevents autoimmune type I diabetes in animal model

Compugen Ltd., announced today that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.

9 Oct 2013

Alkermes announces plans to advance ALKS 5461 phase 3 program for major depressive disorder

Alkermes plc today announced that it has successfully completed its End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA), and the company plans to advance ALKS 5461 into phase 3 development in early 2014.

9 Oct 2013

Studies suggest infusion of blood vessel cells may contribute to organ regeneration in future

Damaged or diseased organs may someday be healed with an injection of blood vessel cells, eliminating the need for donated organs and transplants, according to scientists at Weill Cornell Medical College.

9 Oct 2013

New method for improving cord blood transplant success

Starting with a discovery in zebrafish in 2007, Harvard Stem Cell Institute researchers have published initial results of a Phase Ib human clinical trial of a therapeutic that has the potential to improve the success of blood stem cell transplantation.

9 Oct 2013

Salk scientist receives Career Development Award for new research from JDRF

The Juvenile Diabetes Research Foundation has given Salk scientist Mark Huising a five-year, $750,000 Career Development Award for his proposed study on how a novel network of receptors in human islets receives and integrates molecular signals. In pre-clinical models, activation of these receptors has proven to actually prevent diabetes.

9 Oct 2013

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP).

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the second clinical trial of Glial Growth Factor 2 (GGF2). This Phase 1b single-infusion trial in people with heart failure will assess tolerability of three dose levels of GGF2, and also includes several explorative measures of efficacy.

9 Oct 2013

CARUNDA24: A non-invasive continuous blood pressure measurement system

Freienbach, Switzerland: About 1 in 4 people in Switzerland suffer from high blood pressure; worldwide more than 1 billion people are affected increasing the risk of heart attack, cerebral haemorrhage or a stroke. Unfortunately, most affected people don't measure their blood pressure regularly as the measurement method is too complicated and uncomfortable to be part of a daily routine.

8 Oct 2013

Preclinical News and Research

Pieris, Zydus Cadila partner to develop and commercialize Anticalin-based protein therapeutics

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Tepnel Pharma Services uses Hologic’s Invader Plus technology to offer genotyping, CNV service

New optical imaging technique can accurately differentiate breast cancer subtypes

Novartis Inks Agreement For Immunogen's "TAP" ADC Technology

Yale Launches Collaboration With ARO, CRO Partners

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

Constellation Pharmaceuticals awarded grant to facilitate study of epigenetic control of inflammation

Allegro receives FDA IND approval to initiate Phase II clinical studies of ALG-1001 in AMD, VMT patients

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Catalyst, Isu Abxis To Develop Hemophilia B Candidate

Compugen drug candidate prevents autoimmune type I diabetes in animal model

Alkermes announces plans to advance ALKS 5461 phase 3 program for major depressive disorder

Studies suggest infusion of blood vessel cells may contribute to organ regeneration in future

New method for improving cord blood transplant success

Salk scientist receives Career Development Award for new research from JDRF

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

CARUNDA24: A non-invasive continuous blood pressure measurement system

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics